Kyowa Kirin Discontinues All Rocatinlimab Clinical Trials

Reuters03-04

Kyowa Kirin Discontinues All Rocatinlimab Clinical Trials

Kyowa Kirin Co., Ltd. announced it is discontinuing all ongoing clinical trials for rocatinlimab, an investigational anti-OX40 monoclonal antibody being studied in moderate-to-severe atopic dermatitis, moderate-to-severe uncontrolled asthma, and prurigo nodularis. The decision followed a planned safety update from the global program, with Kyowa Kirin and Amgen concluding that potential risks may outweigh benefits for the studied patient populations. A recent safety review identified emerging concerns of malignancies with possible viral or immune-related links, including one new confirmed case and one suspected case of Kaposi's sarcoma in addition to a previously confirmed case; the companies said the overall number of malignancy cases remains below expected background rates. Kyowa Kirin and Amgen said they are notifying investigators and regulators and will terminate studies after required safety follow-up visits, while conducting a comprehensive analysis of the full dataset.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyowa Kirin Co. Ltd. published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616583199?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 13:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616583199","market":"nz","top_or_hot":-1,"title":"Kyowa Kirin Discontinues All Rocatinlimab Clinical Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kyowa Kirin Discontinues All Rocatinlimab Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kyowa Kirin Co., Ltd. announced it is discontinuing all ongoing clinical trials for rocatinlimab, an investigational anti-OX40 monoclonal antibody being studied in moderate-to-severe atopic dermatitis, moderate-to-severe uncontrolled asthma, and prurigo nodularis. The decision followed a planned safety update from the global program, with Kyowa Kirin and Amgen concluding that potential risks may outweigh benefits for the studied patient populations. A recent safety review identified emerging concerns of malignancies with possible viral or immune-related links, including one new confirmed case and one suspected case of Kaposi's sarcoma in addition to a previously confirmed case; the companies said the overall number of malignancy cases remains below expected background rates. Kyowa Kirin and Amgen said they are notifying investigators and regulators and will terminate studies after required safety follow-up visits, while conducting a comprehensive analysis of the full dataset.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyowa Kirin Co. Ltd. published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kyowa Kirin Discontinues All Rocatinlimab Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKyowa Kirin Discontinues All Rocatinlimab Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-04 13:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kyowa Kirin Discontinues All Rocatinlimab Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kyowa Kirin Co., Ltd. announced it is discontinuing all ongoing clinical trials for rocatinlimab, an investigational anti-OX40 monoclonal antibody being studied in moderate-to-severe atopic dermatitis, moderate-to-severe uncontrolled asthma, and prurigo nodularis. The decision followed a planned safety update from the global program, with Kyowa Kirin and Amgen concluding that potential risks may outweigh benefits for the studied patient populations. A recent safety review identified emerging concerns of malignancies with possible viral or immune-related links, including one new confirmed case and one suspected case of Kaposi's sarcoma in addition to a previously confirmed case; the companies said the overall number of malignancy cases remains below expected background rates. Kyowa Kirin and Amgen said they are notifying investigators and regulators and will terminate studies after required safety follow-up visits, while conducting a comprehensive analysis of the full dataset.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyowa Kirin Co. Ltd. published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL1XNxfz:1","article_id":"2616583199","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616583199","pubTimestamp":1772600858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kyowa Kirin Co., Ltd. announced it is discontinuing all ongoing clinical trials for rocatinlimab, an investigational anti-OX40 monoclonal antibody being studied in moderate-to-severe atopic dermatitis, moderate-to-severe uncontrolled asthma, and prurigo nodularis. The decision followed a planned safety update from the global program, with Kyowa Kirin and Amgen concluding that potential risks may outweigh benefits for the studied patient populations. A recent safety review identified emerging concerns of malignancies with possible viral or immune-related links, including one new confirmed case and one suspected case of Kaposi's sarcoma in addition to a previously confirmed case; the companies said the overall number of malignancy cases remains below expected background rates. Kyowa Kirin and Amgen said they are notifying investigators and regulators and will terminate studies after required safety follow-up visits, while conducting a comprehensive analysis of the full dataset.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","BK4599":"减肥药","LU0058720904.USD":"联博国际健康护理基金A","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","BK4585":"ETF&股票定投概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4534":"瑞士信贷持仓","BK4139":"生物科技","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","AMGN":"安进","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4588":"碎股","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2"},"translate_title":"协和麒麟终止所有Rocatinlimab临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":0.9},"content_text":"Kyowa Kirin Discontinues All Rocatinlimab Clinical Trials\n    \n\n        Kyowa Kirin Co., Ltd. announced it is discontinuing all ongoing clinical trials for rocatinlimab, an investigational anti-OX40 monoclonal antibody being studied in moderate-to-severe atopic dermatitis, moderate-to-severe uncontrolled asthma, and prurigo nodularis. The decision followed a planned safety update from the global program, with Kyowa Kirin and Amgen concluding that potential risks may outweigh benefits for the studied patient populations. A recent safety review identified emerging concerns of malignancies with possible viral or immune-related links, including one new confirmed case and one suspected case of Kaposi's sarcoma in addition to a previously confirmed case; the companies said the overall number of malignancy cases remains below expected background rates. Kyowa Kirin and Amgen said they are notifying investigators and regulators and will terminate studies after required safety follow-up visits, while conducting a comprehensive analysis of the full dataset.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyowa Kirin Co. Ltd. published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616583199","isCrawlerRequest":true}